AvaliaÃÃo do efeito neuroprotetor da Pentoxifilina em modelos de convulsÃo induzidos por Pilocarpina e Pentilenotetrazol em ratos

Detalhes bibliográficos
Autor(a) principal: Rafaelly Maria Pinheiro Siqueira
Data de Publicação: 2011
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Biblioteca Digital de Teses e Dissertações da UFC
Texto Completo: http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=7046
Resumo: Epilepsy is considered one of the most important brain diseases in all whole world and its prevalence reaches 5%. Pilocarpine (P400) is a cholinergic agonist which is characterized by its capacity to induce seizures that evolutes to status epilepticus similar to human temporal lobus epilepsy. Pentylenetetrazole is a GABA antagonist that imitates the absence seizures and tonic-clonic seizures in humans. In this study it was evaluated the neuroprotective properties of Pentoxifylline, a xantin, on the seizures induced by P400 (400mg/kg, i.p.) and PTZ (80 mg/Kg, i.p.) in male Wistar rats (180 â 200g) in the presence or absence of PTX (25 and 50 mg/kg) administered orally 1 h before seizures induction. After PTZ80 injection it was observed the presence of tonic-clonic seizures. After P400 injection we observed peripheral cholinergic signals, 1st seizure latency and survival index. It was also determined the levels of amino acids in the frontal cortex, temporal lobus, hippocampus and striatum as well as the levels of amines in the striatum through HPLC associated to electrochemical detection. The glicemic levels were determined during the acute phase of seizures process. The results show that pentoxifylline does not alter the peripheral cholinergic signals, nevertheless it increases the 1st seizure latency at the dose of 25 mg/kg in 18% when compared to P400 and increases the same parameter (151.8% and 273.5%) at the doses of 25 mg/kg and 50 mg/kg, respectively, when compared to PTZ80. The survival index increased 32% to both doses when compared to P400 and 36% and 71%, respectively when compared to PTZ80. In the frontal cortex it was observed a significative reduction of glutamate at the groups treated with pentoxifilin. Reduction of 86.4% and 76.2% (25 and 50mg/kg PTX) in relation to P400. The levels of GABA reduced 33.3% and 21.8%. In the temporal cortex reduction of 56.6% and 54.8% on the levels of aspartate PTX (25 and 50mg/kg, respectively). The levels of glutamate reduced 78.2% and 59.2% at the tested doses, respectively. The levels of GABA increased 28% at the dose of 50 mg/kg. On the hippocampus aspartate increased 199.6% at the dose of 25 mg/kg. The levels of GABA increased 511% and 180.9% PTX (25 e 50mg/Kg, respectively). In the striatum glutamate reduced with both tested doses 74.3% and 79.4%. GABA reduced 65.6% and 74%. In the striatum dopamine increased 416.5% at the dose of 25 mg/kg. The levels of DOPAC reduced 48% at the same dose. Serotonin increased 229.5%. All amino acids and amines were quantified in the model of pilocarpine induced seizures. It was observed a markedly increase at the glicemic levels at the groups P400 when compared to Normal group and PTX pretreated groups which have by the way kept glicemic levels similar to normal rats. In conclusion we showed that pentoxifilin significantly increases the 1st seizure latency at both tested models. Pentoxifylline neuroprotection may be related to reduction on the levels of excitatory amino acids and increase in the levels of inhibitory amino acids at different parts of the brain involved in the start, propagation and maintenance of epilepsy. Keeping the glicemic levels similar to the normal could be involved in the neuroprotection induced by pentoxifylline.
id UFC_7ba3c36a3dbdb905b6925933ab1f1ccf
oai_identifier_str oai:www.teses.ufc.br:5035
network_acronym_str UFC
network_name_str Biblioteca Digital de Teses e Dissertações da UFC
spelling info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisAvaliaÃÃo do efeito neuroprotetor da Pentoxifilina em modelos de convulsÃo induzidos por Pilocarpina e Pentilenotetrazol em ratos2011-10-27Glauce Socorro de Barros Viana00101761368http://lattes.cnpq.br/5043495454602083Nylane Maria Nunes de Alencar32184573353http://lattes.cnpq.br/9219662256316695Danielle MacÃdo Gaspar50160176387http://lattes.cnpq.br/156693733295736900421398302http://lattes.cnpq.br/9890438853219979 Rafaelly Maria Pinheiro SiqueiraUniversidade Federal do CearÃPrograma de PÃs-GraduaÃÃo em FarmacologiaUFCBRPentoxifylline Seizures Pilocarpine PenyilenetetrazoleConvulsÃoFARMACOLOGIAEpilepsy is considered one of the most important brain diseases in all whole world and its prevalence reaches 5%. Pilocarpine (P400) is a cholinergic agonist which is characterized by its capacity to induce seizures that evolutes to status epilepticus similar to human temporal lobus epilepsy. Pentylenetetrazole is a GABA antagonist that imitates the absence seizures and tonic-clonic seizures in humans. In this study it was evaluated the neuroprotective properties of Pentoxifylline, a xantin, on the seizures induced by P400 (400mg/kg, i.p.) and PTZ (80 mg/Kg, i.p.) in male Wistar rats (180 â 200g) in the presence or absence of PTX (25 and 50 mg/kg) administered orally 1 h before seizures induction. After PTZ80 injection it was observed the presence of tonic-clonic seizures. After P400 injection we observed peripheral cholinergic signals, 1st seizure latency and survival index. It was also determined the levels of amino acids in the frontal cortex, temporal lobus, hippocampus and striatum as well as the levels of amines in the striatum through HPLC associated to electrochemical detection. The glicemic levels were determined during the acute phase of seizures process. The results show that pentoxifylline does not alter the peripheral cholinergic signals, nevertheless it increases the 1st seizure latency at the dose of 25 mg/kg in 18% when compared to P400 and increases the same parameter (151.8% and 273.5%) at the doses of 25 mg/kg and 50 mg/kg, respectively, when compared to PTZ80. The survival index increased 32% to both doses when compared to P400 and 36% and 71%, respectively when compared to PTZ80. In the frontal cortex it was observed a significative reduction of glutamate at the groups treated with pentoxifilin. Reduction of 86.4% and 76.2% (25 and 50mg/kg PTX) in relation to P400. The levels of GABA reduced 33.3% and 21.8%. In the temporal cortex reduction of 56.6% and 54.8% on the levels of aspartate PTX (25 and 50mg/kg, respectively). The levels of glutamate reduced 78.2% and 59.2% at the tested doses, respectively. The levels of GABA increased 28% at the dose of 50 mg/kg. On the hippocampus aspartate increased 199.6% at the dose of 25 mg/kg. The levels of GABA increased 511% and 180.9% PTX (25 e 50mg/Kg, respectively). In the striatum glutamate reduced with both tested doses 74.3% and 79.4%. GABA reduced 65.6% and 74%. In the striatum dopamine increased 416.5% at the dose of 25 mg/kg. The levels of DOPAC reduced 48% at the same dose. Serotonin increased 229.5%. All amino acids and amines were quantified in the model of pilocarpine induced seizures. It was observed a markedly increase at the glicemic levels at the groups P400 when compared to Normal group and PTX pretreated groups which have by the way kept glicemic levels similar to normal rats. In conclusion we showed that pentoxifilin significantly increases the 1st seizure latency at both tested models. Pentoxifylline neuroprotection may be related to reduction on the levels of excitatory amino acids and increase in the levels of inhibitory amino acids at different parts of the brain involved in the start, propagation and maintenance of epilepsy. Keeping the glicemic levels similar to the normal could be involved in the neuroprotection induced by pentoxifylline.A Epilepsia à considerada um dos mais importantes distÃrbios cerebrais em todo o mundo e apresenta uma taxa de prevalÃncia de 5%. A Pilocarpina (P400) à um agonista colinÃrgico que se caracteriza por induzir convulsÃes que evoluem para status epilÃpticus, similar à epilepsia do lobo temporal humana. O Pentilenotetrazol (PTZ) à um antagonista de GABA que mimetiza convulsÃes do pequeno-mal (crise de ausÃncia) e do tipo tÃnico-clÃnico em humanos. Neste presente trabalho avaliamos a possÃvel aÃÃo neuroprotetora da Pentoxifilina (PTX), uma xantina, nas convulsÃes induzidas pela P400 (400mg/kg, i.p.) e PTZ (80mg/Kg, i.p.) em ratos Wistar machos adultos (180 - 220g), na presenÃa ou ausÃncia de PTX (25 e 50mg/kg) administrada por via oral uma Ãnica vez 1 h antes da induÃÃo da convulsÃo. ApÃs a aplicaÃÃo do PTZ80 foi observada a presenÃa de convulsÃes tÃnico-clÃnica. ApÃs a injeÃÃo de P400 foram observados os sinais colinÃrgicos perifÃricos, as latÃncias de 1 convulsÃo e taxa de sobrevida em 24 h. Foram determinadas as concentraÃÃes de aminoÃcidos no cÃrtex frontal, temporal, hipocampo e corpo estriado e as concentraÃÃes de aminas no corpo estriado atravÃs de HPLC com detecÃÃo eletroquÃmica e as alteraÃÃes glicÃmicas na fase aguda do processo convulsivo. Os resultados mostraram que a pentoxifilina nÃo alterou os sinais colinÃrgicos perifÃricos, contudo na dose de 25mg/Kg aumentou a latÃncia decorrida para a primeira convulsÃo em 18% quando comparada ao grupo P400 e aumentou a latÃncia decorrida para a primeira convulsÃo (151,8% e 273,5%) nas doses de 25 e 50mg/Kg respectivamente em relaÃÃo ao grupo PTZ80. A taxa de sobrevida aumentou em 32% em ambas as doses de PTX quando comparado ao grupo controle P400 e em 36% e 71%, respectivamente, quando comparada ao grupo controle PTZ80. No cÃrtex frontal, houve uma reduÃÃo significativa nos nÃveis de glutamato nos grupos prÃ-tratados com pentoxifilina. ReduÃÃo de 86,4% e 76,2% (25 e 50mg/Kg de PTX) em relaÃÃo ao grupo P400. Os nÃveis de GABA reduziram 33,3% e 21,8%. No cÃrtex temporal houve reduÃÃo de 56,6% e 54,8% nos nÃveis de aspartato nos grupos tratados com PTX (25 e 50mg/Kg respectivamente). Os nÃveis de glutamato reduziram 78,2% e 59,2% nas doses testadas respectivamente. Os nÃveis de GABA aumentaram 28% na dose de 50mg/Kg de PTX. No hipocampo, os nÃveis de aspartato aumentaram 199,6% na dose de 25mg/Kg. Os nÃveis de GABA aumentaram 511% e 180,9% nos grupos tratados com PTX (25 e 50mg/Kg respectivamente). No corpo estriado, os nÃveis de glutamato reduziram 74,3% e 79,4% nos grupos tratados (PTX 25 e 50mg/Kg respectivamente). Os nÃveis de GABA reduziram 65,6% e 74%. No corpo estriado, os nÃveis de dopamina aumentaram 416,5% no grupo prÃ-tratado com pentoxifilina na dose de 25mg/Kg. Os nÃveis de DOPAC reduziram 48% no PTX 25mg/Kg. Os nÃveis de serotonina aumentaram 229,5% no PTX 25mg/Kg. Todos os aminoÃcidos e aminas foram quantificados no modelo de convulsÃo por pilocarpina. Houve um acentuado aumento nos nÃveis glicÃmicos em 274,9% no grupo P400, em relaÃÃo ao grupo Normal e os grupos prÃ-tratados com pentoxifilina que em ambas as doses mantiveram os nÃveis glicÃmicos prÃximos do grupo normal. Em conclusÃo, mostramos que a pentoxifilina aumentou significativamente a latÃncia de convulsÃes em ambos os modelos de induÃÃo utilizados. A neuroproteÃÃo da pentoxifilina pode estar relacionada com reduÃÃo dos nÃveis de aminoÃcidos excitatÃrios e aumento de aminoÃcidos inibitÃrios em diferentes Ãreas cerebrais envolvidas com inÃcio, propagaÃÃo e manutenÃÃo da epilepsia. A manutenÃÃo dos nÃveis glicÃmicos prÃximos dos normais pode estar possivelmente relacionada com efeitos neuroprotetores da pentoxifilina.FundaÃÃo Cearense de Apoio ao Desenvolvimento Cientifico e TecnolÃgicohttp://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=7046application/pdfinfo:eu-repo/semantics/openAccessporreponame:Biblioteca Digital de Teses e Dissertações da UFCinstname:Universidade Federal do Cearáinstacron:UFC2019-01-21T11:20:04Zmail@mail.com -
dc.title.pt.fl_str_mv AvaliaÃÃo do efeito neuroprotetor da Pentoxifilina em modelos de convulsÃo induzidos por Pilocarpina e Pentilenotetrazol em ratos
title AvaliaÃÃo do efeito neuroprotetor da Pentoxifilina em modelos de convulsÃo induzidos por Pilocarpina e Pentilenotetrazol em ratos
spellingShingle AvaliaÃÃo do efeito neuroprotetor da Pentoxifilina em modelos de convulsÃo induzidos por Pilocarpina e Pentilenotetrazol em ratos
Rafaelly Maria Pinheiro Siqueira
ConvulsÃo
FARMACOLOGIA
title_short AvaliaÃÃo do efeito neuroprotetor da Pentoxifilina em modelos de convulsÃo induzidos por Pilocarpina e Pentilenotetrazol em ratos
title_full AvaliaÃÃo do efeito neuroprotetor da Pentoxifilina em modelos de convulsÃo induzidos por Pilocarpina e Pentilenotetrazol em ratos
title_fullStr AvaliaÃÃo do efeito neuroprotetor da Pentoxifilina em modelos de convulsÃo induzidos por Pilocarpina e Pentilenotetrazol em ratos
title_full_unstemmed AvaliaÃÃo do efeito neuroprotetor da Pentoxifilina em modelos de convulsÃo induzidos por Pilocarpina e Pentilenotetrazol em ratos
title_sort AvaliaÃÃo do efeito neuroprotetor da Pentoxifilina em modelos de convulsÃo induzidos por Pilocarpina e Pentilenotetrazol em ratos
author Rafaelly Maria Pinheiro Siqueira
author_facet Rafaelly Maria Pinheiro Siqueira
author_role author
dc.contributor.advisor1.fl_str_mv Glauce Socorro de Barros Viana
dc.contributor.advisor1ID.fl_str_mv 00101761368
dc.contributor.advisor1Lattes.fl_str_mv http://lattes.cnpq.br/5043495454602083
dc.contributor.referee1.fl_str_mv Nylane Maria Nunes de Alencar
dc.contributor.referee1ID.fl_str_mv 32184573353
dc.contributor.referee1Lattes.fl_str_mv http://lattes.cnpq.br/9219662256316695
dc.contributor.referee2.fl_str_mv Danielle MacÃdo Gaspar
dc.contributor.referee2ID.fl_str_mv 50160176387
dc.contributor.referee2Lattes.fl_str_mv http://lattes.cnpq.br/1566937332957369
dc.contributor.authorID.fl_str_mv 00421398302
dc.contributor.authorLattes.fl_str_mv http://lattes.cnpq.br/9890438853219979
dc.contributor.author.fl_str_mv Rafaelly Maria Pinheiro Siqueira
contributor_str_mv Glauce Socorro de Barros Viana
Nylane Maria Nunes de Alencar
Danielle MacÃdo Gaspar
dc.subject.por.fl_str_mv ConvulsÃo
topic ConvulsÃo
FARMACOLOGIA
dc.subject.cnpq.fl_str_mv FARMACOLOGIA
dc.description.sponsorship.fl_txt_mv FundaÃÃo Cearense de Apoio ao Desenvolvimento Cientifico e TecnolÃgico
dc.description.abstract..fl_txt_mv Epilepsy is considered one of the most important brain diseases in all whole world and its prevalence reaches 5%. Pilocarpine (P400) is a cholinergic agonist which is characterized by its capacity to induce seizures that evolutes to status epilepticus similar to human temporal lobus epilepsy. Pentylenetetrazole is a GABA antagonist that imitates the absence seizures and tonic-clonic seizures in humans. In this study it was evaluated the neuroprotective properties of Pentoxifylline, a xantin, on the seizures induced by P400 (400mg/kg, i.p.) and PTZ (80 mg/Kg, i.p.) in male Wistar rats (180 â 200g) in the presence or absence of PTX (25 and 50 mg/kg) administered orally 1 h before seizures induction. After PTZ80 injection it was observed the presence of tonic-clonic seizures. After P400 injection we observed peripheral cholinergic signals, 1st seizure latency and survival index. It was also determined the levels of amino acids in the frontal cortex, temporal lobus, hippocampus and striatum as well as the levels of amines in the striatum through HPLC associated to electrochemical detection. The glicemic levels were determined during the acute phase of seizures process. The results show that pentoxifylline does not alter the peripheral cholinergic signals, nevertheless it increases the 1st seizure latency at the dose of 25 mg/kg in 18% when compared to P400 and increases the same parameter (151.8% and 273.5%) at the doses of 25 mg/kg and 50 mg/kg, respectively, when compared to PTZ80. The survival index increased 32% to both doses when compared to P400 and 36% and 71%, respectively when compared to PTZ80. In the frontal cortex it was observed a significative reduction of glutamate at the groups treated with pentoxifilin. Reduction of 86.4% and 76.2% (25 and 50mg/kg PTX) in relation to P400. The levels of GABA reduced 33.3% and 21.8%. In the temporal cortex reduction of 56.6% and 54.8% on the levels of aspartate PTX (25 and 50mg/kg, respectively). The levels of glutamate reduced 78.2% and 59.2% at the tested doses, respectively. The levels of GABA increased 28% at the dose of 50 mg/kg. On the hippocampus aspartate increased 199.6% at the dose of 25 mg/kg. The levels of GABA increased 511% and 180.9% PTX (25 e 50mg/Kg, respectively). In the striatum glutamate reduced with both tested doses 74.3% and 79.4%. GABA reduced 65.6% and 74%. In the striatum dopamine increased 416.5% at the dose of 25 mg/kg. The levels of DOPAC reduced 48% at the same dose. Serotonin increased 229.5%. All amino acids and amines were quantified in the model of pilocarpine induced seizures. It was observed a markedly increase at the glicemic levels at the groups P400 when compared to Normal group and PTX pretreated groups which have by the way kept glicemic levels similar to normal rats. In conclusion we showed that pentoxifilin significantly increases the 1st seizure latency at both tested models. Pentoxifylline neuroprotection may be related to reduction on the levels of excitatory amino acids and increase in the levels of inhibitory amino acids at different parts of the brain involved in the start, propagation and maintenance of epilepsy. Keeping the glicemic levels similar to the normal could be involved in the neuroprotection induced by pentoxifylline.
dc.description.abstract.por.fl_txt_mv A Epilepsia à considerada um dos mais importantes distÃrbios cerebrais em todo o mundo e apresenta uma taxa de prevalÃncia de 5%. A Pilocarpina (P400) à um agonista colinÃrgico que se caracteriza por induzir convulsÃes que evoluem para status epilÃpticus, similar à epilepsia do lobo temporal humana. O Pentilenotetrazol (PTZ) à um antagonista de GABA que mimetiza convulsÃes do pequeno-mal (crise de ausÃncia) e do tipo tÃnico-clÃnico em humanos. Neste presente trabalho avaliamos a possÃvel aÃÃo neuroprotetora da Pentoxifilina (PTX), uma xantina, nas convulsÃes induzidas pela P400 (400mg/kg, i.p.) e PTZ (80mg/Kg, i.p.) em ratos Wistar machos adultos (180 - 220g), na presenÃa ou ausÃncia de PTX (25 e 50mg/kg) administrada por via oral uma Ãnica vez 1 h antes da induÃÃo da convulsÃo. ApÃs a aplicaÃÃo do PTZ80 foi observada a presenÃa de convulsÃes tÃnico-clÃnica. ApÃs a injeÃÃo de P400 foram observados os sinais colinÃrgicos perifÃricos, as latÃncias de 1 convulsÃo e taxa de sobrevida em 24 h. Foram determinadas as concentraÃÃes de aminoÃcidos no cÃrtex frontal, temporal, hipocampo e corpo estriado e as concentraÃÃes de aminas no corpo estriado atravÃs de HPLC com detecÃÃo eletroquÃmica e as alteraÃÃes glicÃmicas na fase aguda do processo convulsivo. Os resultados mostraram que a pentoxifilina nÃo alterou os sinais colinÃrgicos perifÃricos, contudo na dose de 25mg/Kg aumentou a latÃncia decorrida para a primeira convulsÃo em 18% quando comparada ao grupo P400 e aumentou a latÃncia decorrida para a primeira convulsÃo (151,8% e 273,5%) nas doses de 25 e 50mg/Kg respectivamente em relaÃÃo ao grupo PTZ80. A taxa de sobrevida aumentou em 32% em ambas as doses de PTX quando comparado ao grupo controle P400 e em 36% e 71%, respectivamente, quando comparada ao grupo controle PTZ80. No cÃrtex frontal, houve uma reduÃÃo significativa nos nÃveis de glutamato nos grupos prÃ-tratados com pentoxifilina. ReduÃÃo de 86,4% e 76,2% (25 e 50mg/Kg de PTX) em relaÃÃo ao grupo P400. Os nÃveis de GABA reduziram 33,3% e 21,8%. No cÃrtex temporal houve reduÃÃo de 56,6% e 54,8% nos nÃveis de aspartato nos grupos tratados com PTX (25 e 50mg/Kg respectivamente). Os nÃveis de glutamato reduziram 78,2% e 59,2% nas doses testadas respectivamente. Os nÃveis de GABA aumentaram 28% na dose de 50mg/Kg de PTX. No hipocampo, os nÃveis de aspartato aumentaram 199,6% na dose de 25mg/Kg. Os nÃveis de GABA aumentaram 511% e 180,9% nos grupos tratados com PTX (25 e 50mg/Kg respectivamente). No corpo estriado, os nÃveis de glutamato reduziram 74,3% e 79,4% nos grupos tratados (PTX 25 e 50mg/Kg respectivamente). Os nÃveis de GABA reduziram 65,6% e 74%. No corpo estriado, os nÃveis de dopamina aumentaram 416,5% no grupo prÃ-tratado com pentoxifilina na dose de 25mg/Kg. Os nÃveis de DOPAC reduziram 48% no PTX 25mg/Kg. Os nÃveis de serotonina aumentaram 229,5% no PTX 25mg/Kg. Todos os aminoÃcidos e aminas foram quantificados no modelo de convulsÃo por pilocarpina. Houve um acentuado aumento nos nÃveis glicÃmicos em 274,9% no grupo P400, em relaÃÃo ao grupo Normal e os grupos prÃ-tratados com pentoxifilina que em ambas as doses mantiveram os nÃveis glicÃmicos prÃximos do grupo normal. Em conclusÃo, mostramos que a pentoxifilina aumentou significativamente a latÃncia de convulsÃes em ambos os modelos de induÃÃo utilizados. A neuroproteÃÃo da pentoxifilina pode estar relacionada com reduÃÃo dos nÃveis de aminoÃcidos excitatÃrios e aumento de aminoÃcidos inibitÃrios em diferentes Ãreas cerebrais envolvidas com inÃcio, propagaÃÃo e manutenÃÃo da epilepsia. A manutenÃÃo dos nÃveis glicÃmicos prÃximos dos normais pode estar possivelmente relacionada com efeitos neuroprotetores da pentoxifilina.
description Epilepsy is considered one of the most important brain diseases in all whole world and its prevalence reaches 5%. Pilocarpine (P400) is a cholinergic agonist which is characterized by its capacity to induce seizures that evolutes to status epilepticus similar to human temporal lobus epilepsy. Pentylenetetrazole is a GABA antagonist that imitates the absence seizures and tonic-clonic seizures in humans. In this study it was evaluated the neuroprotective properties of Pentoxifylline, a xantin, on the seizures induced by P400 (400mg/kg, i.p.) and PTZ (80 mg/Kg, i.p.) in male Wistar rats (180 â 200g) in the presence or absence of PTX (25 and 50 mg/kg) administered orally 1 h before seizures induction. After PTZ80 injection it was observed the presence of tonic-clonic seizures. After P400 injection we observed peripheral cholinergic signals, 1st seizure latency and survival index. It was also determined the levels of amino acids in the frontal cortex, temporal lobus, hippocampus and striatum as well as the levels of amines in the striatum through HPLC associated to electrochemical detection. The glicemic levels were determined during the acute phase of seizures process. The results show that pentoxifylline does not alter the peripheral cholinergic signals, nevertheless it increases the 1st seizure latency at the dose of 25 mg/kg in 18% when compared to P400 and increases the same parameter (151.8% and 273.5%) at the doses of 25 mg/kg and 50 mg/kg, respectively, when compared to PTZ80. The survival index increased 32% to both doses when compared to P400 and 36% and 71%, respectively when compared to PTZ80. In the frontal cortex it was observed a significative reduction of glutamate at the groups treated with pentoxifilin. Reduction of 86.4% and 76.2% (25 and 50mg/kg PTX) in relation to P400. The levels of GABA reduced 33.3% and 21.8%. In the temporal cortex reduction of 56.6% and 54.8% on the levels of aspartate PTX (25 and 50mg/kg, respectively). The levels of glutamate reduced 78.2% and 59.2% at the tested doses, respectively. The levels of GABA increased 28% at the dose of 50 mg/kg. On the hippocampus aspartate increased 199.6% at the dose of 25 mg/kg. The levels of GABA increased 511% and 180.9% PTX (25 e 50mg/Kg, respectively). In the striatum glutamate reduced with both tested doses 74.3% and 79.4%. GABA reduced 65.6% and 74%. In the striatum dopamine increased 416.5% at the dose of 25 mg/kg. The levels of DOPAC reduced 48% at the same dose. Serotonin increased 229.5%. All amino acids and amines were quantified in the model of pilocarpine induced seizures. It was observed a markedly increase at the glicemic levels at the groups P400 when compared to Normal group and PTX pretreated groups which have by the way kept glicemic levels similar to normal rats. In conclusion we showed that pentoxifilin significantly increases the 1st seizure latency at both tested models. Pentoxifylline neuroprotection may be related to reduction on the levels of excitatory amino acids and increase in the levels of inhibitory amino acids at different parts of the brain involved in the start, propagation and maintenance of epilepsy. Keeping the glicemic levels similar to the normal could be involved in the neuroprotection induced by pentoxifylline.
publishDate 2011
dc.date.issued.fl_str_mv 2011-10-27
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
status_str publishedVersion
format masterThesis
dc.identifier.uri.fl_str_mv http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=7046
url http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=7046
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal do CearÃ
dc.publisher.program.fl_str_mv Programa de PÃs-GraduaÃÃo em Farmacologia
dc.publisher.initials.fl_str_mv UFC
dc.publisher.country.fl_str_mv BR
publisher.none.fl_str_mv Universidade Federal do CearÃ
dc.source.none.fl_str_mv reponame:Biblioteca Digital de Teses e Dissertações da UFC
instname:Universidade Federal do Ceará
instacron:UFC
reponame_str Biblioteca Digital de Teses e Dissertações da UFC
collection Biblioteca Digital de Teses e Dissertações da UFC
instname_str Universidade Federal do Ceará
instacron_str UFC
institution UFC
repository.name.fl_str_mv -
repository.mail.fl_str_mv mail@mail.com
_version_ 1643295155068862464